Vacunación contra el covid-19 en la población pediátrica

Abstract

The objective of this research is to determine the vaccination against COVID-19 in the child population. This study is quantitative, descriptive, cross-sectional and prospective; and it was applied to the pediatric population of the Pinguili parish of the Mocha canton, province of Tungurahua, Ecuador. The population consisted of children over 1 year old up to 14 years old, who received the vaccine against COVID-19. Applying the finite population formula, with a margin of error of 5 and a reliability index of 95, a significant sample of 172 patients was obtained. The collection instrument was the "Notification Form for Events Supposedly Attributable to Vaccination or Immunization" of the Ministry of Health of Argentina. The results showed a predominance of immunized children between the ages of 10 to 14 years, corresponding to 52%. The most widely used vaccine was the one manufactured by the pharmaceutical company Sinovac (59% of cases). The most frequent adverse reaction was pain, while a combination of systemic adverse reactions was seen in several children of which fever was the most frequent. There was no illness attributable to vaccination against COVID-19. On the contrary, a spontaneous improvement of the symptomatology of the adverse effects caused by vaccination was evidenced in all cases. It is concluded that the majority of the pediatric population has been immunized with the COVID-19 vaccine and the local and systemic adverse effects resolved spontaneously without the need for specialized medication.